Action GENOMIC HEALTH, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues Genomic Health, Inc.

Actions

US37244C1018

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
MDxHealth SA acquired Oncotype DX GPS Prostate Cancer Business from Genomic Health, Inc. for approximately $100 million.
Biocartis Group NV and Biocartis and Genomic Health, Inc. Agree to End Collaboration Due to Changed Market Circumstances
Genomic Health, Inc. Announces Executive Changes
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P 1000
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P 600 Health Care
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P 600
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P Global BMI Index
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P Composite 1500
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P TMI Index
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P Biotechnology Select Industry Index
Genomic Health, Inc.(NasdaqGM:GHDX) dropped from NASDAQ Composite Index
Exact Sciences Corporation completed the acquisition of Exact Sciences Corporation from Baker Bros. Advisors LP and others.
Genomic Health : Stockholders Approve Proposed Acquisition by Exact Sciences
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from NASDAQ Biotechnology Index
Genomic Health Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
Genomic Health : New TAILORx Data, Published Today in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy Treatment
Genomic Health, Inc. Announces Results from a New Analysis of the Trial Assigning IndividuaLised Options for Treatment (Rx), or TAILORx
Genomic Health : New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage Breast Cancer
New St. Gallen International Breast Cancer Guidelines Recommends Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage Breast Cancer
WeissLaw LLP Investigates Genomic Health, Inc.
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action
  4. Actualités Genomic Health, Inc.
  5. Autres langues